Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Biotechnology

Biocon Limited, together with its subsidiaries, engages in the manufacture and sale of biotechnology products and research services in India, Brazil, Singapore, and internationally. It operates through four segments: Generics, Novel Biologics, Biosimilars, and Research Services. The company offers generic formulations and API products, including anti-diabetics, immunosuppressants, multiple sclerosis, anti-cancer/oncology, and other products; novel biologics products, such as head and neck cancer molecule; novel pipeline products comprising psoriasis molecules; and biosimilars products consisting of insulins, trastuzumab, pegfilgrastim, and bevacizumab. It also provides integrated discovery, development, and manufacturing services to pharmaceutical, biotechnology, animal healthcare, consumer good, and agrochemical companies. Biocon Limited was incorporated in 1978 and is headquartered in Bengaluru, India.

Revenue projections:

Revenue projections for BIOCON
Revenue projections for BIOCON

Biocon Limited's revenue projections show a decrease from last year, which tends to make investors more cautious. This could have a negative impact on the company's bottom line, as lower revenues typically suggest reduced profitability and growth potential, prompting concern among investors.

Financial Ratios:

currentRatio 0.000000
forwardPE 41.827625
debtToEquity 50.024000
earningsGrowth 4.095000
revenueGrowth 0.092000
grossMargins 0.608710
operatingMargins 0.076250
trailingEps 4.880000
forwardEps 9.179340

BIOCON's forward EPS is greater than its trailing EPS, indicating that the company is expected to deliver higher profitability this year. This suggests that BIOCON is projected to improve its earnings, reflecting positive growth compared to last year's financial performance.

Price projections:

Price projections for BIOCON
Price projections for BIOCON

BIOCON's price has consistently been situated near the lower end of expected values. This ongoing trend may reflect investor skepticism about the company's growth potential and overall performance.

Recommendation changes over time:

Recommendations trend for BIOCON
Recommendations trend for BIOCON


Analysts have shown a buy bias for BIOCON, marking it as a favorable investment option. This could inspire investors to see BIOCON as a strong place to park their money, given the positive outlook and growth potential associated with the stock in recent evaluations.